Intradermal powder immunization with protein-containing vaccines

Expert Review of Vaccines

Volumn 12, Issue 6, 2013, Pages 687-702

  Weissmueller, Nikolas T ^a,b   Schiffter, Heiko A ^b   Pollard, Andrew J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

epidermal powder immunization; immunogenicity; intradermal injection; microparticles; needle free

Indexed keywords

ALUMINUM SALT; BACTERIAL TOXIN; CPG OLIGODEOXYNUCLEOTIDE; CRYOPROTECTIVE AGENT; DIPHTHERIA TOXOID; GAMMA INTERFERON; HEPATITIS B SURFACE ANTIGEN; INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; INTERLEUKIN 4; INTERLEUKIN 5; ORAL POLIOMYELITIS VACCINE; OVALBUMIN; SAPONIN DERIVATIVE; TETANUS TOXOID; TUMOR NECROSIS FACTOR ALPHA; VACCINE; VIRUS ENVELOPE PROTEIN; VIRUS PROTEIN; IMMUNOLOGICAL ADJUVANT; POWDER; PROTEIN;

ADJUVANT THERAPY; DESENSITIZATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERABILITY; EQUINE HERPES VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; INJECTION SITE EDEMA; INOCULATION; MEASLES VACCINATION; NEEDLE; NONHUMAN; PETECHIA; POWDER; PRIORITY JOURNAL; REVIEW; SKIN INJURY; SKIN PENETRATION; VACCINATION; ADMINISTRATION AND DOSAGE; ANIMAL; IMMUNIZATION; IMMUNOLOGY; INTRADERMAL DRUG ADMINISTRATION; PROCEDURES;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; HUMANS; IMMUNIZATION; INJECTIONS, INTRADERMAL; POWDERS; PROTEINS; VACCINES;

EID: 84879042176     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.13.48     Document Type: Review

References (89)

1. Varmus H, Klausner R, Zerhouni E, Acharya T, Daar AS, Singer PA. Public health. Grand challenges in global health. Science 302(5644), 398-399 (2003). (Pubitemid 37296252)
2. Senior K. New vaccination technologies that make needles redundant. Lancet Infect. Dis. 11(1), 16-17 (2011).
3. Amorij JP, Hinrichs WLj, Frijlink HW, Wilschut JC, Huckriede A. Needle-free influenza vaccination. Lancet Infect. Dis. 10(10), 699-711 (2010).
4. Mitragotri S. Immunization without needles. Nat. Rev. Immunol. 5(12), 905-916 (2005). (Pubitemid 41746760)
5. Prausnitz MR, Langer R. Transdermal drug delivery. Nat. Biotechnol. 26(11), 1261-1268 (2008).
6. WHO. Safety of Injections: Global Facts and Figures. WHO, Geneva, Switzerland (2004).
7. Kermode M. Unsafe injections in low-income country health settings: need for injection safety promotion to prevent the spread of blood-borne viruses. Health Promot. Int. 19(1), 95-103 (2004). (Pubitemid 38364808)
8. WHO. State of the world's vaccines and immunizations. JAMA 288(20), 2532 (2002).
9. Wilburn SQ, Eijkemans G. Preventing needle stick injuries among healthcare workers. J. Adv. Nurs. 50(4), 450-450 (2005).
10. CDC. Impact of vaccines universally recommended for children-United States, 1990-1998. MMWR 48, 243-248 (1999).
11. Das P. Revolutionary vaccine technology breaks the cold chain. Lancet Infect. Dis. 4(12), 719 (2004).
12. Jódar L, LaForce FM, Ceccarini C, Aguado T, Granoff DM. Meningococcal conjugate vaccine for Africa: a model for development of new vaccines for the poorest countries. Lancet 361(9372), 1902-1904 (2003). (Pubitemid 36645189)
13. Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nat. Rev. Immunol. 6(2), 148-158 (2006). (Pubitemid 43361590)
14. Girardi M. Cutaneous perspectives on adaptive immunity. Clin. Rev. Allergy Immunol. 33(1-2), 4-14 (2007).
15. Zhaori G, Sun M, Ogra PL. Characteristics of the immune response to poliovirus virion polypeptides after immunization with live or inactivated polio vaccines. J. Infect. Dis. 158(1), 160-165 (1988).
16. Fernandez-De Castro J, Kumate-Rodriguez J, Sepulveda J, Ramirez-Isunza JM, Valdespino-Gomez JL. [Measles vaccination by the aerosol method in Mexico]. Salud Publica Mex. 39(1), 53-60 (1997). (Pubitemid 27128959)
17. Lin WH, Griffin DE, Rota PA et al. Successful respiratory immunization with dry powder live-attenuated measles virus vaccine in rhesus macaques. Proc. Natl Acad. Sci. USA 108(7), 2987-2992 (2011).
18. Woodrow KA, Bennett KM, Lo DD. Mucosal vaccine design and delivery. Annu. Rev. Biomed. Eng. 14, 17-46 (2012).
19. Chase MW. Inhibition of experimental drug allergy by prior feeding of the sensitizing agent. Proc. Soc. Exp. Biol. Med. 61, 257-259 (1946).
20. Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat. Med. 11(4 Suppl.), S45-S53 (2005). (Pubitemid 40562303)
21. Canter J, Mackey K, Good LS et al. An outbreak of hepatitis B associated with jet injections in a weight reduction clinic. Arch. Intern. Med. 150(9), 1923-1927 (1990). (Pubitemid 20316539)
22. Jackson LA, Austin G, Chen RT et al.; Vaccine Safety Datalink Study Group. Safety and immunogenicity of varying dosages of trivalent inactivated influenza vaccine administered by needle-free jet injectors. Vaccine 19(32), 4703-4709 (2001). (Pubitemid 32800754)
23. Sullivan SP, Koutsonanos DG, Del Pilar Martin M et al. Dissolving polymer microneedle patches for influenza vaccination. Nat. Med. 16(8), 915-920 (2010).
24. Dean HJ, Chen D. Epidermal powder immunization against influenza. Vaccine 23(5), 681-686 (2004). (Pubitemid 39473199)
25. Ekwueme DU, Weniger BG, Chen RT. Model-based estimates of risks of disease transmission and economic costs of seven injection devices in sub-Saharan Africa. Bull. World Health Organ. 80(11), 859-870 (2002). (Pubitemid 35408258)
26. Prausnitz MR, Mikszta JA, Cormier M, Andrianov AK. Microneedle-based vaccines. Curr. Top. Microbiol. Immunol. 333, 369-393 (2009).
27. Wang W. Protein aggregation and its inhibition in biopharmaceutics. Int. J. Pharm. 289(1-2), 1-30 (2005).
28. Chen D, Endres RL, Erickson CA et al. Epidermal immunization by a needle-free powder delivery technology: immunogenicity of influenza vaccine and protection in mice. Nat. Med. 6(10), 1187-1190 (2000).
29. Maa YF, Ameri M, Shu C, Payne LG, Chen D. Influenza vaccine powder formulation development: spray-freeze-drying and stability evaluation. J. Pharm. Sci. 93(7), 1912-1923 (2004). (Pubitemid 38823716)
30. Glenn GM, Kenney RT. Mass vaccination: solutions in the skin. Curr. Top. Microbiol. Immunol. 304, 247-268 (2006). (Pubitemid 47413300)
31. Sandby-Møller J, Poulsen T, Wulf HC. Epidermal thickness at different body sites: relationship to age, gender, pigmentation, blood content, skin type and smoking habits. Acta Derm. Venereol. 83(6), 410-413 (2003). (Pubitemid 37475779)
32. Madison KC. Barrier function of the skin: 'la raison d'être' of the epidermis. J. Invest. Dermatol. 121(2), 231-241 (2003). (Pubitemid 36969895)
33. Torin Huzil J, Sivaloganathan S, Kohandel M, Foldvari M. Drug delivery through the skin: molecular simulations of barrier lipids to design more effective noninvasive dermal and transdermal delivery systems for small molecules, biologics, and cosmetics. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. doi:10.1002/wnan.147 (2011) (Epub ahead of print).
34. Bos JD, Meinardi MM. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp. Dermatol. 9(3), 165-169 (2000). (Pubitemid 30255378)
35. Kendall M, Rishworth S, Carter F, Mitchell T. Effects of relative humidity and ambient temperature on the ballistic delivery of micro-particles to excised porcine skin. J. Invest. Dermatol. 122(3), 739-746 (2004). (Pubitemid 38471344)
36. Holbrook KA, Odland GF. Regional differences in the thickness (cell layers) of the human stratum corneum: an ultrastructural analysis. J. Invest. Dermatol. 62(4), 415-422 (1974).
37. Yosipovitch G, Xiong GL, Haus E, Sackett-Lundeen L, Ashkenazi I, Maibach HI. Time-dependent variations of the skin barrier function in humans: transepidermal water loss, stratum corneum hydration, skin surface pH, and skin temperature. J. Invest. Dermatol. 110(1), 20-23 (1998). (Pubitemid 28086057)
38. Darlenski R, Fluhr JW. Influence of skin type, race, sex, and anatomic location on epidermal barrier function. Clin. Dermatol. 30(3), 269-273 (2012).
39. Dean HJ, Fuller D, Osorio JE. Powder and particle-mediated approaches for delivery of DNA and protein vaccines into the epidermis. Comp. Immunol. Microbiol. Infect. Dis. 26(5-6), 373-388 (2003).
40. Hamilton JG. Needle phobia: a neglected diagnosis. J. Fam. Pract. 41(2), 169-175 (1995).
41. Liu Y. Utilization of the venturi effect to introduce micro-particles for epidermal vaccination. Med. Eng. Phys. 29(3), 390-397 (2007). (Pubitemid 44880189)
42. Kendall MAF, Quinlan NJ, Thorpe SJ, Ainsworth RW, Bellhouse BJ. Measurements of the gas and particle flow within a converging-diverging nozzle for high speed powdered vaccine and drug delivery. Exp. Fluids 37(1), 128-136 (2004). (Pubitemid 38935631)
43. Quinlan NJ, Kendall MAF, Bellhouse BJ, Ainsworth RW. Investigations of gas and particle dynamics in first generation needle-free drug delivery devices. Shock Waves 10(6), 395-404 (2001).
44. Kendall M, Mitchell T, Wrighton-Smith P. Intradermal ballistic delivery of micro-particles into excised human skin for pharmaceutical applications. J. Biomech. 37(11), 1733-1741 (2004). (Pubitemid 39237586)
45. Burkoth TL, Bellhouse BJ, Hewson G, Longridge DJ, Muddle AG, Sarphie DF. Transdermal and transmucosal powdered drug delivery. Crit. Rev. Ther. Drug Carrier Syst. 16(4), 331-384 (1999). (Pubitemid 29441806)
46. Koutsonanos DG, Vassilieva EV, Stavropoulou A et al. Delivery of subunit influenza vaccine to skin with microneedles improves immunogenicity and long-lived protection. Sci. Rep. 2, 357 (2012).
47. Abbas A, Lichtman A, Pober J. Cellular and Molecular Immunology. WB Saunders, PA, USA (2000).
48. Kupper TS, Fuhlbrigge RC. Immune surveillance in the skin: mechanisms and clinical consequences. Nat. Rev. Immunol. 4(3), 211-222 (2004). (Pubitemid 38339087)
49. Robert C, Kupper TS. Inflammatory skin diseases, T cells, and immune surveillance. N. Engl. J. Med. 341(24), 1817-1828 (1999).
50. Alcock R, Cottingham MG, Rollier CS et al. Long-term thermostabilization of live poxviral and adenoviral vaccine vectors at supraphysiological temperatures in carbohydrate glass. Sci. Transl. Med. 2(19), 19ra12 (2010).
51. Pipkin PA, Minor PD. Studies on the loss of infectivity of live type 3 poliovaccine on storage. Biologicals 26(1), 17-23 (1998). (Pubitemid 28274490)
52. Milstien JB, Galazka AM, Kartoglu Ü, Zaffran M. Temperature Sensitivity of Vaccines. WHO, Geneva, Switzerland (2006).
53. Weir E, Hatch K. Preventing cold chain failure: vaccine storage and handling. CMAJ 171(9), 1050 (2004). (Pubitemid 39468712)
54. Rogers B, Dennison K, Adepoju N, Dowd S, Uedoi K. Vaccine cold chain: part 1. proper handling and storage of vaccine. AAOHN J. 58(8), 337-344; quiz 345 (2010).
55. Bell KN, Hogue CJ, Manning C, Kendal AP. Risk factors for improper vaccine storage and handling in private provider offices. Pediatrics 107(6), e100 (2001).
56. Chen D, Kristensen D. Opportunities and challenges of developing thermostable vaccines. Expert Rev. Vaccines 8(5), 547-557 (2009).
57. Patel J, Kothari R, Tunga R, Ritter NM, Tunga BS. Stability considerations for biopharmaceuticals, Part 1: Overview of protein and peptide degradation pathways. BioProcess Int. 9(1), 20-31 (2011).
58. Carpenter JF, Pikal MJ, Chang BS, Randolph TW. Rational design of stable lyophilized protein formulations: some practical advice. Pharm. Res. 14(8), 969-975 (1997). (Pubitemid 27371393)
59. Levy Y, Onuchic JN. Water and proteins: a love-hate relationship. Proc. Natl Acad. Sci. USA 101(10), 3325-3326 (2004). (Pubitemid 38338194)
60. Fang WJ, Qi W, Kinzell J, Prestrelski S, Carpenter JF. Effects of excipients on the chemical and physical stability of glucagon during freeze-drying and storage in dried formulations. Pharm. Res. 29(12), 3278-3291 (2012).
61. Yoshioka S, Aso Y. Correlations between molecular mobility and chemical stability during storage of amorphous pharmaceuticals. J. Pharm. Sci. 96(5), 960-981 (2007). (Pubitemid 46797468)
62. Wang W. Lyophilization and development of solid protein pharmaceuticals. Int. J. Pharm. 203(1-2), 1-60 (2000). (Pubitemid 30627625)
63. Chen D, Endres R, Maa YF et al. Epidermal powder immunization of mice and monkeys with an influenza vaccine. Vaccine 21(21-22), 2830-2836 (2003).
64. Chen D, Periwal SB, Larrivee K et al. Serum and mucosal immune responses to an inactivated influenza virus vaccine induced by epidermal powder immunization. J. Virol. 75(17), 7956-7965 (2001). (Pubitemid 32743667)
65. Chen D, Endres RL, Erickson CA, Maa YF, Payne LG. Epidermal powder immunization using non-toxic bacterial enterotoxin adjuvants with influenza vaccine augments protective immunity. Vaccine 20(21-22), 2671-2679 (2002).
66. Chen D, Burger M, Chu Q et al. Epidermal powder immunization: cellular and molecular mechanisms for enhancing vaccine immunogenicity. Virus Res. 103(1-2), 147-153 (2004). (Pubitemid 38649073)
67. Maa YF, Zhao L, Payne LG, Chen D. Stabilization of alum-adjuvanted vaccine dry powder formulations: mechanism and application. J. Pharm. Sci. 92(2), 319-332 (2003). (Pubitemid 36169305)
68. Osorio JE, Zuleger CL, Burger M, Chu Q, Payne LG, Chen D. Immune responses to hepatitis B surface antigen following epidermal powder immunization. Immunol. Cell Biol. 81(1), 52-58 (2003). (Pubitemid 36237792)
69. Maa YF, Shu C, Ameri M et al. Optimization of an alum-adsorbed vaccine powder formulation for epidermal powder immunization. Pharm. Res. 20(7), 969-977 (2003). (Pubitemid 36774266)
70. Maa YF, Ameri M, Rigney R, Payne LG, Chen D. Spray-coating for biopharmaceutical powder formulations: beyond the conventional scale and its application. Pharm. Res. 21(3), 515-523 (2004). (Pubitemid 38338988)
71. Maa YF, Ameri M, Shu C et al. Hepatitis-B surface antigen (HBsAg) powder formulation: process and stability assessment. Curr. Drug Deliv. 4(1), 57-67 (2007). (Pubitemid 46066415)
72. Chen D, Erickson CA, Endres RL et al. Adjuvantation of epidermal powder immunization. Vaccine 19(20-22), 2908-2917 (2001).
73. Chen D, Zuleger C, Chu Q, Maa YF, Osorio J, Payne LG. Epidermal powder immunization with a recombinant HIV gp120 targets Langerhans cells and induces enhanced immune responses. AIDS Res. Hum. Retroviruses 18(10), 715-722 (2002). (Pubitemid 34765340)
74. Kondo T, McGregor M, Chu Q, Chen D, Horimoto T, Kawaoka Y. A protective effect of epidermal powder immunization in a mouse model of equine herpesvirus-1 infection. Virology 318(1), 414-419 (2004). (Pubitemid 38234291)
75. Gupta RK. Aluminum compounds as vaccine adjuvants. Adv. Drug Deliv. Rev. 32(3), 155-172 (1998). (Pubitemid 28267407)
76. Morefield GL, Sokolovska A, Jiang D, HogenEsch H, Robinson JP, Hem SL. Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro. Vaccine 23(13), 1588-1595 (2005). (Pubitemid 40203396)
77. Huleatt JW, Jacobs AR, Tang J et al. Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity. Vaccine 25(4), 763-775 (2007). (Pubitemid 44856106)
78. Sokolovska A, Hem SL, HogenEsch H. Activation of dendritic cells and induction of CD4(+) T cell differentiation by aluminum-containing adjuvants. Vaccine 25(23), 4575-4585 (2007). (Pubitemid 46734537)
79. Jones LS, Peek LJ, Power J, Markham A, Yazzie B, Middaugh CR. Effects of adsorption to aluminum salt adjuvants on the structure and stability of model protein antigens. J. Biol. Chem. 280(14), 13406-13414 (2005). (Pubitemid 40517228)
80. Marsee DK, Williams JM, Velazquez EF. Aluminum granuloma after administration of the quadrivalent human papillomavirus vaccine. Report of a case. Am. J. Dermatopathol. 30(6), 622-624 (2008).
81. Bernasconi NL, Onai N, Lanzavecchia A. A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. Blood 101(11), 4500-4504 (2003). (Pubitemid 36857820)
82. Latz E, Schoenemeyer A, Visintin A et al. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat. Immunol. 5(2), 190-198 (2004). (Pubitemid 38208361)
83. Kendall M, Mitchell TJ, Costigan G et al. Downregulation of IgE antibody and allergic responses in the lung by epidermal biolistic microparticle delivery. J. Allergy Clin. Immunol. 117(2), 275-282 (2006). (Pubitemid 43190140)
84. Burger MS, Zuleger CL, Chu Q, Gao X, Payne LG, Chen D. An antigen-independent but not antigen-specific T(H)1 response provides protection in the murine airway inflammation model. J. Allergy Clin. Immunol. 114(6), 1301-1308 (2004). (Pubitemid 39575882)
85. Tosini W, Ciotti C, Goyer F et al. Needlestick injury rates according to different types of safety-engineered devices: results of a French multicenter study. Infect. Control Hosp. Epidemiol. 31(4), 402-407 (2010).
86. Leleux J, Roy K. Micro and nanoparticlebased delivery systems for vaccine immunotherapy: an immunological and materials perspective. Adv. Healthc. Mater. 2(1), 72-94 (2013).
87. Murdan S, Somavarapu S, Ross AC, Alpar HO, Parker MC. Immobilisation of vaccines onto micro-crystals for enhanced thermal stability. Int. J. Pharm. 296(1-2), 117-121 (2005).
88. Liu Y, Kendall MA. Optimization of a jet-propelled particle injection system for the uniform transdermal delivery of drug/vaccine. Biotechnol. Bioeng. 97(5), 1300-1308 (2007). (Pubitemid 47195324)
89. Kersten G, Hirschberg H. Needle-free vaccine delivery. Expert Opin. Drug. Del 4(5), 459-474 (2007). (Pubitemid 47527329)